An ongoing open-label, multicenter phase 1b/2a study is instead evaluating safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of GNS561 (a new autophagy inhibitor), in combination with trametinib (MEK inhibitor) in advanced KRAS-mutated CCA after failure of standard-of-care first line therapy (NCT05874414). This evidence concerns the gene MAP2K7 and cholangiocarcinoma.